Skip to content

Study · Randomized controlled trial · n = 22 · 2018

3 results

Oral ghrelin receptor agonist MK-0677 increases serum insulin-like growth factor 1 in hemodialysis patients: a randomized blinded study.

Campbell GA, Patrie JT, Gaylinn BD, Thorner MO, Bolton WK

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association1 Mar 2018Cited by 17 (Europe PMC)

PMID28340044 (opens in a new tab)PMCIDPMC6019053 (opens in a new tab)DOI10.1093/ndt/gfw474 (opens in a new tab)PepBankPUB-28340044
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In hemodialysis patients, geometric mean IGF-1 increased 1.76-fold following MK-0677.

    In plain wordsIn hemodialysis patients, MK-0677 increased IGF-1 compared with its pretreatment level.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    IncreaseIGF-1 increase from baseline
    Study

    n = 22

    Analysis
    Primary
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · oral · 3-month crossover studyAs given in this study (human).

    Measurements

    IGF-1 fold change
    1.76 fold
    MK-0677
    95% confidence interval for IGF-1 fold change
    1.48 to 2.1 fold
    following MK-0677
    P value
    < 0.001
    IGF-1 pre- versus postintervention change following MK-0677

    Source sentences

    Summary
    In patients receiving MK-0677, the geometric mean IGF-1 were 1.76-fold greater (95% CI 1.48-2.10; P < 0.001) following MK-0677.
    2 context sentences
    Summary · context
    We performed a randomized crossover double-blind study in assessing the effect of MK-0677 versus placebo on IGF-1 levels, the primary outcome, in hemodialysis patients.
    Summary · context
    In total, 26 subjects enrolled and 22 completed the 3-month crossover study.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In hemodialysis patients, MK-0677 produced a 65% greater IGF-1 increase than placebo.

    In plain wordsIn hemodialysis patients, MK-0677 increased IGF-1 more than placebo.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    IncreaseIGF-1 increase versus placebo
    Study

    n = 22

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · oral · 3-month crossover studyAs given in this study (human).

    Measurements

    Greater IGF-1 increase
    65%
    versus placebo
    Adjusted ratio of geometric means
    1.65 ratio
    MK-0677 relative to placebo
    95% confidence interval for greater IGF-1 increase
    33 to 104%
    MK-0677 versus placebo
    95% confidence interval for adjusted ratio of geometric means
    1.33 to 2.04 ratio
    MK-0677 relative to placebo, adjusted for preintervention IGF-1
    P value
    < 0.001
    adjusted ratio of geometric means for IGF-1 pre- versus postintervention change: MK-0677 versus placebo

    Source sentences

    Summary
    These data demonstrate a 65% greater increase (95% CI 33-104%) in IGF-1 in MK-0677-dosed subjects compared with placebo.
    3 context sentences
    Summary · context
    When the data were adjusted for preintervention IGF-1 concentration, the ratio of geometric means (MK-0677 relative to placebo) for the pre- versus postintervention change in the IGF-1 was 1.65 (95% CI 1.33-2.04; P < 0.001).
    Summary · context
    We performed a randomized crossover double-blind study in assessing the effect of MK-0677 versus placebo on IGF-1 levels, the primary outcome, in hemodialysis patients.
    Summary · context
    In total, 26 subjects enrolled and 22 completed the 3-month crossover study.
  3. 03HumanRandomized controlled trialSafety outcome

    In hemodialysis patients, no serious adverse effects were attributable to MK-0677.

    In plain wordsIn hemodialysis patients, the study reported no serious adverse effects attributable to MK-0677.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    Not applicableAttributable serious adverse effects
    Study

    n = 22

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · oral · 3-month crossover studyAs given in this study (human).

    Source sentences

    Summary
    There were no serious adverse effects attributable to MK-0677.
    2 context sentences
    Summary · context
    We performed a randomized crossover double-blind study in assessing the effect of MK-0677 versus placebo on IGF-1 levels, the primary outcome, in hemodialysis patients.
    Summary · context
    In total, 26 subjects enrolled and 22 completed the 3-month crossover study.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.